Related Experiment Video
Updated: Nov 9, 2025

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Association between COVID-19 morbidity and mortality rates and BCG vaccination policies in OECD countries
Yuki Senoo1,2, Yosuke Suzuki1,3, Kenji Tsuda1,4
1Medical Governance Research Institute, Minato-ward, Tokyo, Japan.
Insights
The Bacillus Calmette-Guérin vaccination (BCGV) policy may reduce coronavirus disease 2019 (COVID-19) cases. Countries with BCGV policies showed fewer COVID-19 cases and deaths compared to those without.
Area of Science:
- Immunology
- Epidemiology
- Public Health
Background:
- The global impact of coronavirus disease 2019 (COVID-19) necessitates understanding potential protective factors.
- The Bacillus Calmette-Guérin vaccination (BCGV) is a widely implemented vaccine with known immunomodulatory effects.
- Variations in national BCGV policies exist among Organisation for Economic Co-operation and Development (OECD) countries.
Purpose of the Study:
- To investigate the association between national BCG vaccination policies and COVID-19 outcomes.
- To determine if BCGV implementation influences COVID-19 morbidity and mortality rates.
- To explore the potential protective role of BCGV against COVID-19.
Main Methods:
- Comparative analysis of COVID-19 morbidity and mortality data.
- Examination of national BCG vaccination policies in OECD countries.
- Statistical comparison between countries with and without established BCGV policies.
Main Results:
- Countries currently implementing a national BCGV policy exhibited lower rates of COVID-19 morbidity.
- A significant reduction in COVID-19 mortality was observed in nations with existing BCGV policies.
- Comparison revealed fewer COVID-19 cases in countries with versus without a BCGV policy.
Conclusions:
- The findings suggest a potential protective effect of BCGV against COVID-19.
- National BCGV policies may be associated with reduced COVID-19 burden.
- Further research is warranted to elucidate the mechanisms behind BCGV's potential impact on COVID-19.
Abstract:
We compared whether the national BCG vaccination (BCGV) policy influenced coronavirus disease 2019 (COVID-19) in Organisation for Economic Co-operation and Development (OECD) countries. Those currently implementing BCGV have a reduced number of COVID-19 morbidity and mortality cases, compared to those who have never implemented a BCGV policy, suggesting the potential protective effect of BCGV against COVID-19.
More Related Videos
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
08:10A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb BCG lux/M.Tb lux
Published on: September 14, 2011
Related Concept Videos
Vaccinations
Bias in Epidemiological Studies
Causality in Epidemiology
Factors Affecting Illness
For instance, risk factors are connected to illness,...
Principles of Disease Surveillance
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...